Compare MLAB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLAB | ZVRA |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.9M | 689.4M |
| IPO Year | 1995 | 2015 |
| Metric | MLAB | ZVRA |
|---|---|---|
| Price | $127.56 | $10.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $117.50 | $25.00 |
| AVG Volume (30 Days) | 89.9K | ★ 849.5K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 436.11 | 159.21 |
| EPS | 0.49 | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $2.14 | $43.97 |
| Revenue Next Year | $6.45 | $15.93 |
| P/E Ratio | $261.37 | ★ $15.30 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $69.43 | $8.01 |
| 52 Week High | $144.35 | $15.04 |
| Indicator | MLAB | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 39.50 |
| Support Level | $89.77 | $10.07 |
| Resistance Level | $132.70 | $11.07 |
| Average True Range (ATR) | 5.03 | 0.48 |
| MACD | -1.26 | 0.01 |
| Stochastic Oscillator | 15.89 | 34.14 |
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.